For the quarter ending 2026-01-31, ZEOX had $809K increase in cash & cash equivalents over the period. -$485K in free cash flow.
| Cash Flow | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|
| Reserve of non- marketable securities related party | - | - | 0 |
| Write-off of advances payable to former officer | - | - | 0 |
| Security deposits | - | - | 0 |
| Net loss | -852 | -815 | -4,706 |
| Depreciation and amortization expense | 19 | 20 | 53 |
| Amortization of debt discount promissory notes | - | 39 | - |
| Inducement expense to convert notes | - | 136 | - |
| Amortization of oid and commitment fee discount promissory notes | -16 | - | 18 |
| Bad debt expense | - | 0 | - |
| Stock-based compensation | 592 | 756 | 3,937 |
| Change in obligation to repurchase shares | -19 | 0 | 2 |
| Accounts receivable, net of allowance for bad debts | 27 | 35 | -194 |
| Other receivable | - | -1 | -2 |
| Prepaid expenses | 134 | -212 | 237 |
| Inventories | 79 | 165 | 26 |
| Accounts payable and accrued expenses | -9 | -403 | 603 |
| Deferred revenue | 36 | -111 | -175 |
| Net cash (used in) provided by operating activities | -471 | -383 | -335 |
| Investment in non-marketable equity securities related party | - | - | 0 |
| Purchase of fixed assets | 14 | 0 | 23 |
| Net cash used in financing activities | -14 | 0 | -23 |
| Proceeds from sale of common stock | 1,300 | 300 | 0 |
| Proceeds from exercise of warrants | - | 0 | 50 |
| Payments on finance leases | 6 | 10 | 35 |
| Net cash provided by (used in) financing activities | 1,294 | 290 | 15 |
| Increase in cash | 809 | -93 | -343 |
| Cash at beginning of period | 221 | 657 | - |
| Cash at end of period | 1,030 | 221 | - |
Zeo ScientifiX, Inc. (ZEOX)
Zeo ScientifiX, Inc. (ZEOX)